David D. Hurd, MD

Professor, Hematology and Oncology

David D. Hurd, MD

Professor, Hematology and Oncology

About Me

Education: BS, University of Wisconsin - Madison, 1969; MD, University of Illinois College of Medicine, 1974
Internship: Internal Medicine, University of Minnesota, 1975
Residency: Internal Medicine, University of Minnesota, 1977
Fellowship: University of Minnesota, 1979
Board Certifications: American Board of Internal Medicine, Internal Medicine; American Board of Internal Medicine, Medical Oncology
Memberships: American Association of Cancer Research; American College of Physicians; American Society of Clinical Oncology; American Society of Hematology; AAAS
Positions: Professor, Hematology and Oncology
Departments and Affiliations: Hematology and Oncology

Research

Publications

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. Clin. Cancer Res. 2018 05; 24(9):2060-2073.
Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G. Leuk. Lymphoma. 2018 08; 59(8):1871-1877.
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DD. Clin Lymphoma Myeloma Leuk. 2017 07; 17(7):424-432.
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma. Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):76-81.

View More Publications

More Resources

More Resources

Institutes and Centers

Shared Resources and Cores

Research and Faculty Labs

Clinical Trials

Symposia Series

David D. Hurd, MD

David D. Hurd, MD

About Me